ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.188,34
-1,00%
S&P 500
5.214,08
0,51%
US Dollar vs BRL
5,1407
1,01%
Bitcoin
62.740,38
2,54%
Brent Oil
83,95
0,47%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. CTI BioPharma Corporation (CTIC)

  7. CTI BioPharma Corporation (CTIC) Notícias

CTIC

CTI BioPharma (CTIC)

CTI BioPharma Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTIC
DataHoraFonteTítuloCódigoCompanhia
06/07/202317:15Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:CTICCTI BioPharma Corporation
30/06/202307:08Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CTICCTI BioPharma Corporation
30/06/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTICCTI BioPharma Corporation
28/06/202319:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CTICCTI BioPharma Corporation
28/06/202319:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTICCTI BioPharma Corporation
28/06/202314:51Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CTICCTI BioPharma Corporation
26/06/202318:07Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CTICCTI BioPharma Corporation
26/06/202317:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CTICCTI BioPharma Corporation
26/06/202311:35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CTICCTI BioPharma Corporation
26/06/202310:21Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:CTICCTI BioPharma Corporation
26/06/202309:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CTICCTI BioPharma Corporation
26/06/202307:08Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:CTICCTI BioPharma Corporation
24/06/202307:51PR Newswire (US)Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.NASDAQ:CTICCTI BioPharma Corporation
30/05/202317:35PR Newswire (US)CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of StockholdersNASDAQ:CTICCTI BioPharma Corporation
25/05/202308:01Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:CTICCTI BioPharma Corporation
25/05/202307:46Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:CTICCTI BioPharma Corporation
15/05/202317:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CTICCTI BioPharma Corporation
10/05/202315:03Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:CTICCTI BioPharma Corporation
10/05/202302:06PR Newswire (US)Sobi to Acquire CTI BioPharmaNASDAQ:CTICCTI BioPharma Corporation
04/05/202320:55PR Newswire (US)CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CTICCTI BioPharma Corporation
01/05/202317:46PR Newswire (US)CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023NASDAQ:CTICCTI BioPharma Corporation
01/05/202308:03PR Newswire (US)CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CTICCTI BioPharma Corporation
28/04/202317:14Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:CTICCTI BioPharma Corporation
28/04/202317:08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CTICCTI BioPharma Corporation
14/04/202309:26Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CTICCTI BioPharma Corporation
12/04/202317:30PR Newswire (US)CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023NASDAQ:CTICCTI BioPharma Corporation
06/03/202318:32Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CTICCTI BioPharma Corporation
06/03/202308:25PR Newswire (US)CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:CTICCTI BioPharma Corporation
01/03/202318:20PR Newswire (US)CTI BioPharma to Present at the 43rd Annual Cowen Health Care ConferenceNASDAQ:CTICCTI BioPharma Corporation
23/02/202309:03PR Newswire (US)CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023NASDAQ:CTICCTI BioPharma Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTIC

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
PDTC3
Padtec ON
BOV
AZEV4
AZEVEDO PN
BOV
OIBR3
OI ON
BOV
VVEO3
CM Hospitalar ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
PRIO3
PETRORIO ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
ENJU3
Enjoei ON
BOV
ENAT3
ENAUTA ON
BOV
JHSF3
JHSF PART ON
BOV
SGPS3
SPRINGS ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados